Table 1 Clinical and immunophenotypical characteristics of DLBCL patients
Features | No. of Patients (%) |
|---|---|
Age (years) | 62 |
< 60 | 31 (38) |
≥ 60 | 51 (62) |
Sex Male/Female | 48 /34 (59/41) |
IPI | |
0–2 | 42 (51) |
≥ 3 | 40 (49) |
IPI Age adjusted (IPIaa) | |
0 | 17 (21) |
1 | 27 (33) |
2 | 20 (24) |
3 | 18 (22) |
Ann Arbor stage | |
I/II | 29 (35) |
III/IV | 53 (65) |
Serum lactate dehydrogenase (>1x normal) | 41 (51) |
Pathological type | |
GCB | 49 (60) |
Non-GCB | 33 (40) |
Therapy regimen | R-CHOP |
Median follow-up time, months | 53.7 (0.4–202.6) |
5-year OS | 65.9 |
5-year PFS | 60.6 |